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Supporting Methods. 
 
In vitro PA studies. Bacterial plasmids encoding several far-red GFP-like FPs were kindly 
provided by Benjamin Glick (University of Chicago, USA) and Dmitry Chudakov and 
Konstantin Lukyanov (both from the Institute of Bioorganic Chemistry, Moscow, Russia). 
Recombinant GFP-like FPs were expressed in LMG194 bacterial cells and purified using a 
Ni-NTA agarose (Qiagen). The purified FP solutions were diluted to equal concentrations of 
32 µM. 
For determining the best FP for PA imaging, a phantom consisted of approximately 
20.00 mm long, 0.30 mm inner diameter (i.d.) tubing sections (Silastic Laboratory) filled with 
one of the FP samples or blood. The tubes were then glued in parallel onto a flat gelatin block 
and imaged at 600 nm and 680 nm with ~90 mJ incident energy, using a 512 element ring 
transducer PACT system with top illumination from an OPO laser (Vibrant 335 I)[1]. The 
wavelengths were chosen to cover wavelengths near the peak excitation of each of FPs. The 
signal amplitude was compensated for laser power differences using a photodiode signal for 
normalization, and the signal from each FP was further normalized to blood absorption for 
comparison. 
The depth analysis phantom consisted of approximately 20.00 mm long, 1.47 mm i.d. 
tubing sections (Silastic Laboratory) filled with either iRFP or blood for comparison. The 
sections were then embedded in the chicken breast tissue and imaged using deep-PAM, with 
illumination provided by a Ti-Sapphire laser (LT-2211A) at 700 nm and approximately 100 
mJ incident energy[2]. Deep-PAM was used for its reflection mode geometry, allowing for 
easier simulation of depth imaging. The illumination wavelength of 700 nm enabled delivery 
of greater laser energy with a similar protein absorption efficiency. Additional depths were 
simulated by stacking sections of chicken breast tissue on the sample surface. Twenty B-
mode images were averaged at each depth. The noise equivalent concentration was calculated 
by dividing the known concentration of the absorber by the SNR of the sample, and provided 
an estimate of the expected minimum concentration detectable by the system for this sample. 
Mammalian plasmids and cell culture. A pEGFP-C1 vector (Clontech) was utilized 
to construct plasmids for iRFP mammalian expression and to create a stable line. The iRFP 
gene was PCR-amplified to have the Kozak sequence on its 5’-terminus and inserted into the 
NheI and KpnI sites of the vector, thus generating a piRFP plasmid. The MTLn3 cell line (rat 
adenocarcinoma) was grown in alphaMEM containing 5% fetal bovine serum (FBS) and 
penicillin-streptomycin. Plasmid transfection was performed using an Effectene reagent 
(Qiagen) according to the manufacturer’s protocol. Stably-expressing cells were selected with 
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700 mg/ml G418 antibiotic. Sorting of positive cells was performed using a MoFlo XDP 
sorter (Beckman Coulter) equipped with a 676 nm Kr laser and a 700 nm LP emission filter. 
Stably EGFP-expressing and TagRFP657-expressing MTLn3 cells were described 
previously[3]. 
 In vivo fluorescent imaging and PA studies. One million of the MTLn3 cells stably 
expressing iRFP, TagRFP657 or EGFP were injected into the mammary gland of SCID/NCr 
mice (female), and imaged starting one (iRFP) or two weeks (TagRFP657 and EGFP) after 
that, using an IVIS Spectrum instrument (Caliper Life Sciences) in epifluorescence mode. 
The IVIS Spectrum instrument was equipped with 675/30 nm and 720/20 nm filters (for iRFP 
imaging), 605/30 nm and 660/20 nm filters (for TagRFP657 imaging), and 465/30 nm and 
520/20 (for EGFP imaging) for excitation and emission, respectively. Belly fur was removed 
using a depilatory cream. When required, 250 nmol of BV were injected intravenously. iRFP- 
or EGFP-expressing tumors were excised postmortem. For the FACS analysis using MoFlo 
XDP, tumors were chopped into pieces, washed with a phosphate buffered solution 
supplemented with 2% of bovine serum albumin, and subsequently filtered through sieves 
and FACS filter. 
For PACT, two mice were imaged at the tumor region at two weeks and three weeks 
post inoculation using three wavelengths, 700 nm, 760 nm, and 796 nm. For spectral 
separation, the images were then processed using a linear least squares method for the three 
absorbers[4]. For clear separation from blood, the wavelengths were chosen such that 
absorption by iRFP is near the maximum at 700 nm, and essentially zero at the other 
wavelengths.  
Two and three weeks post injection, a 15 mm by 15 mm area was imaged using the 
deep-PAM system. Images were taken at the same near-IR wavelengths as the PACT 
experiment, with depth simulated by stacking approximately 4 mm of the chicken breast 
tissue over the sample. The same least square method was performed for spectral separation 
at both depths. To assess the iRFP concentration, we assumed the average total hemoglobin 
concentration to be similar through the depths imaged, and we normalized the calculated 
concentrations of iRFP to the average total hemoglobin concentration at each depth. Given 
the literature value for total hemoglobin concentration of 2.3 mM, the estimated maximum 
iRFP concentration would then be between 21 to 22 µM. 
All animal experiments were performed in an AAALAC approved facility, using 
protocols approved by the Washington University in St. Louis Animal Use Committee. 
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Supporting Figure 1. Fluorescent whole-body imaging of the mice 1 week after the injection 
of the iRFP-expressing cancer cells. 
 
 
 
One million of the MTLn3 cells stably expressing iRFP were injected into the mammary 
gland of SCID/NCr mice and imaged starting one week after that using IVIS Spectrum 
instrument (Caliper LifeSciences) in epifluorescence mode equipped with 675/30 nm and 
720/20 nm filters for excitation and emission, respectively. The belly fur was removed using 
a depilatory cream. The injection site is shown with yellow circle. The color bar indicates the 
fluorescence radiant efficiency (p s-1 sr-1 µW-1 cm-2) multiplied by 107.  
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Supporting Figure 2. Direct BV injection into the iRFP-expressing tumor. 
 
 
 
75 nmol BV in DMSO was injected directly into the tumor. The next day the mouse was 
sacrificed and the tumor was isolated and dissected into the halves (a). The injection site 
(indicated by the arrow) is ~1.5 fold brighter as calculated by measuring of the total radiant 
efficiency in injected area and non-injected area of the same square (b). Non-uniform BV 
distribution in tumor after direct injection precludes fluorescence brightness-based time-
course measurements. 
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Supporting Figure 3. PACT imaging of the 2 week old iRFP-expressing tumor. 
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Using the PACT setup described previously, three images on the left were taken at different 
wavelengths (indicated); the main image is a spectrally separated one, with the tumor in blue 
and the blood in red. Color bars represent normalized PA amplitude (bottom) or the spectrally 
resolved iRFP and blood signals normalized to the spectrally resolved blood signal (right). 
The position of the tumor is labeled with the yellow arrow. The white dashed line shows the 
mouse body borders.  
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Supporting Figure 4. Deep-PAM imaging of the cross-section of the 2 week old iRFP-
expressing tumor. 
 
 
 
Using the deep-PAM system described previously, three images on the left were taken with 
no tissue overlay (a) and with 6 mm tissue overlay (b) at different wavelengths (indicated); 
the main image is a spectrally separated one, with the tumor in blue and the blood in red. 
Color bars represent normalized PA amplitude (bottom) or the spectrally resolved iRFP and 
blood signals normalized to the spectrally resolved blood signal (right). The position of the 
tumor is labeled with the yellow arrow. The white dashed line shows the mouse body 
borders.  
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Supporting Table 1. Spectral properties of the fluorescent proteins used in the paper. 
 
FPs 
Excitation 
maximum 
(nm) 
Emission 
maximum 
(nm) 
Molar 
extinction 
coefficient 
(M-1 cm-1) 
Quantum yield 
of fluorescence 
Molar extinction 
coefficient x Non-
radiative quantum 
yield (M-1 cm-1) 
mKate2[5] 588 633 56,400 0.39 34,404 
mNeptune[5] 600 650 59,000 0.20 47,200 
eqFP670[6] 605 670 70,000 0.06 65,800 
E2-Crimson[6] 605 646 58,500 0.12 51,480 
TagRFP657[5] 611 657 34,000 0.10 30,600 
iRFP[7] 690 713 105,000 0.06 98,700 
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